GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small study. Here's what doctors have to say.

A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.

Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified pr ...

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

Once you have accepted that inquiry demands the presence of an interlocutor, you may wonder what exactly to inquire about.

Oral semaglutide administered via the RaniPill® HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

As weight loss jabs soar in popularity, many people have turned to online pharmacies and websites to get the medications without having to see a doctor. However, this will change as online pharmacies ...

Biomed Industrie, Inc. logo NA-931 for weight loss Biomed pipeline Biomed Industries, Inc. Engages with Medicare to Advan ...

Novo Nordisk NVO is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks ...